AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$DGX

Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcript

Quest Diagnostics (DGX) raised its full-year revenue and earnings guidance after Q3 2026, citing strong performance across physician, hospital, and consumer health channels. Key growth drivers include collaborations, acquisitions, and innovative solutions like Apple Health app integration. The company also announced plans to expand its Alzheimer's disease testing portfolio and improve operational efficiency through automation and AI.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 5:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 6:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$DGXBullishHigh
01

Why it matters

The guidance raise and acquisition signal continued expansion and operational efficiency, likely supporting a higher valuation.

02

Market read

Strong earnings guidance and strategic acquisitions make Quest Diagnostics a notable mover in the healthcare services space.

03

What to watch

Potential regulatory or reimbursement risks could temper upside.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Quest Diagnostics discussed growth across clinical, hospital, consumer health, and advanced diagnostics channels, and announced a pending acquisition of outreach assets.

Company-level read

Ticker impact

$DGXBullishHigh confidence
Context

Quest Diagnostics raised full-year revenue and EPS guidance during its Q3 2026 earnings call, indicating stronger outlook.

Expected impact

likely upward pressure as investors price in stronger guidance

Evidence & confidence

Guidance upgrades for a large-cap lab services provider typically drive short-term price gains.

Market effects

Sector

May boost sentiment for healthcare services and diagnostics sector.

Regional

Positive for US healthcare stocks, limited broader market effect.

Global

Limited to investors tracking US lab services and related biotech partnerships.

Counterpoint

What could challenge this read

If guidance already priced in, the upgrade may be modestly overvalued.

Key entities

  • partner
    Fresenius Medical Care

    Collaboration partner mentioned in kidney diagnostics.

  • partner
    Corewell Health

    Co-Lab Solutions partnership driving hospital revenue.

Read at source← All news

StoryQuest Diagnostics posts Q3 2026 results, raises full‑year revenue and EPS outlook

Also covered by

6 outlets

Related articles

OCT 22
$DGXLow

Quest Diagnostics Reports Hack on IT System Used by Clients

Quest Diagnostics reported a cyber incident involving its Quanum Lab Services Manager system, potentially compromising certain patient records. The company paused access to the system while investigating but stated it has not materially disrupted operations. Quest notified U.S. law enforcement and is taking remedial measures. The company reported $11.04 billion in revenue for 2025. This follows recent cyber incidents at Abbott Labs, which is facing lawsuits.

govinfosecurity.com2 min
OCT 22
$DGXMed

Quest Diagnostics Inc (DGX) (Q3 2026) Earnings Call Highlights: Double-Digit Revenue

Quest Diagnostics (DGX) reported Q3 2026 earnings with double-digit revenue growth, but faces challenges. PAMA reimbursement cuts may impact 2027 revenues by 1%. Total revenue per requisition declined 4.2% due to business mix, though it rose 1.7% excluding certain relationships. The company also reported a cybersecurity incident and higher fuel costs. CEO Jim Davis and CFO Sam Samad discussed growth strategies, partnerships, and margin improvements.

finance.yahoo.com3 min
OCT 22
$DGXHighAI 8/10

What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call

Quest Diagnostics (DGX) reported Q3 operating income of $479M, up from $386M YoY. Adjusted EPS rose 15.4% to $3.00. The company expects full-year 2026 revenue of $12.065B-$12.105B. Quest plans to acquire select assets from a health system in the Northeastern U.S. and launched consumer health services via Apple Health app. Management addressed PAMA concerns, estimating a 1% revenue impact in 2027.

finance.yahoo.com2 min
OCT 22
$DGXMedAI 8/10

Quest Diagnostics Incorporated Q3 2026 Earnings Call Summary

Quest Diagnostics reported 10% Q3 2026 revenue growth, driven by strong performance across commercial channels and partnerships. Consumer health revenue is expected to grow over 30% for the year. The company raised full-year 2026 revenue and EPS guidance, citing sustained demand and AI-driven efficiency gains. Management discussed potential PAMA-related revenue impacts and cybersecurity incidents. They plan to offset PAMA headwinds through cost efficiencies and volume growth.

finance.yahoo.com3 min